iRhythm Technologies (NASDAQ:IRTC – Get Rating) and Adynxx (OTCMKTS:ADYX – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.
This is a breakdown of current ratings for iRhythm Technologies and Adynxx, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation and Earnings
This table compares iRhythm Technologies and Adynxx’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|iRhythm Technologies||$322.83 million||12.04||-$101.36 million||($4.21)||-30.98|
Adynxx has lower revenue, but higher earnings than iRhythm Technologies.
This table compares iRhythm Technologies and Adynxx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
97.9% of iRhythm Technologies shares are owned by institutional investors. 1.6% of iRhythm Technologies shares are owned by insiders. Comparatively, 17.4% of Adynxx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
iRhythm Technologies has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Adynxx has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500.
Adynxx beats iRhythm Technologies on 5 of the 8 factors compared between the two stocks.
iRhythm Technologies Company Profile (Get Rating)
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Adynxx Company Profile (Get Rating)
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
Receive News & Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.